肝癌血浆EGFR水平与放疗效果关系研究  

Correlation between the level of plasma EGFR protein and efficacy of radiotherapy in patients with hepatocelluar carcinoma

作　　者：王国栋[1] 党亚正[1] 

机构地区：[1]解放军第三二三医院综合内科,陕西西安710054

出　　处：《现代肿瘤医学》2015年第2期247-249,共3页Journal of Modern Oncology

摘　　要：目的:观察肝癌患者放疗前后血浆表皮生长因子受体(EGFR)水平与放射治疗效果之间的关系。方法:ELISA法检测114例非手术肝癌患者放疗前1天、放疗开始后7天及1个月时血浆EGFR含量。按治疗前血浆EGFR含量分为高水平组与低水平组,分析近期疗效、中位生存时间和1年生存率与EGFR水平间的关系。结果:血浆EGFR高水平组近期有效率(CR+PR)为29.6%,血浆EGFR低水平组近期有效率(CR+PR)为63.3%,差异有统计学意义(P<0.05)。血浆EGFR高、低水平组中位生存时间分别为7、15个月,差异有统计学意义(P<0.05),血浆EGFR高、低水平组1年生存率分别为32.4%、63.9%(P<0.05)。结论:肝癌患者血浆EGFR水平可作为放疗效果预测指标。Objective：To analyze the correlation between the expression level of the plasma epidermal growth factor receptor （EGFR） protein and efficacy of radiotherapy in inpatients suffering from hepatocelluar carcinoma （HCC）.Methods：One hundred-fourteen samples were collected on one day before radiotherapy,seven days and one month after radiotherapy beginning,respectively.The concentration of plasma EGFR protein was detected by ELISA.Results：The short-term efficiency （CR ＋ PR） in high and low EGFR level group were 29.6％ and 63.3％ （P ＜ 0.05）.The median survival time and one year overall survival in high and low EGFR level groups were 7 and 15 months （P ＜ 0.05）,32.4％ and 63.9％ （P ＜ 0.05）,respectively.Conclusion：EGFR protein level in peripheral blood may be a molecular biomarker in prediction of efficacy and survival of the radiotherapy in patients with HCC.

关 键 词：肝细胞癌 放射治疗 表皮生长因子受体 

分 类 号：R735.7[医药卫生—肿瘤]